project id: TCGA-LUAD; case submitter id: TCGA-95-A4VK; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.91; normal tumor genotype snp match: Yes; age at index: 74; days to birth: -27040; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1938; age at diagnosis: 27040; ajcc pathologic m: M0; ajcc pathologic n: N2; ajcc pathologic stage: Stage IIIA; ajcc pathologic t: T2b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 651.0; icd 10 code: C34.1; last known disease status: not reported; morphology: 8255/3; primary diagnosis: Adenocarcinoma with mixed subtypes; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Upper lobe, lung; synchronous malignancy: No; tissue or organ of origin: Upper lobe, lung; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: yes; alcohol history: Not Reported; cigarettes per day: 2.4657534246575343; pack years smoked: 45.0; years smoked: 30.0; is ffpe: false; composition: Not Reported; days to collection: 155; days to sample procurement: 0; initial weight: 140.0; portion submitter id: TCGA-95-A4VK-01A-11; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 1.0; percent necrosis: 10.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 90.0; percent tumor nuclei: 75.0;